![](https://news.europawire.eu/wp-content/uploads/2013/10/roche.jpg)
Roche to acquire Ignyta for US$ 27.00 per share Ignyta’s investigational medicine entrectinib, a selective CNS-active tyrosine-kinase inhibitor being developed for tumours that harbor ROS1 or NTRK fusions, to expand Roche’s portfolio of oncology medicines BASEL, 27-Dec-2017 — /EuropaWire/ — … Read the full press release